Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

There will be scheduled maintenance work beginning on Saturday 15th June 2019 at 8:30 am through to Sunday 16th June 2019 at 11:30 pm (BST).

During this time our website may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 11, 2012
Previous Article Next Article

Small molecules targeting phosphoinositide 3-kinases

Author affiliations

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is one of the most important signaling cascades in cancer, and PI3K is a well established target for anticancer therapy. Since the discovery of the first two compounds that inhibit PI3K, wortmannin and LY294002, a wealth of PI3K inhibitors of various chemotypes have been identified, and nearly twenty of them are currently in various stages of clinical trials. This review outlines the current landscape of the development of small molecule PI3K inhibitors with a focus on structure–activity relationships (SAR) and discussion of co-crystal structures.

Graphical abstract: Small molecules targeting phosphoinositide 3-kinases

Back to tab navigation

Publication details

The article was received on 14 Feb 2012, accepted on 05 May 2012 and first published on 11 May 2012


Article type: Review Article
DOI: 10.1039/C2MD20044A
Med. Chem. Commun., 2012,3, 1337-1355

  •   Request permissions

    Small molecules targeting phosphoinositide 3-kinases

    P. Wu and Y. Hu, Med. Chem. Commun., 2012, 3, 1337
    DOI: 10.1039/C2MD20044A

Search articles by author

Spotlight

Advertisements